Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a clinical-stage biotechnology company that develops targeted RNA interference therapeutics to treat intractable genetic and cardiometabolic diseases. Operating with its proprietary Targeted RNAi Molecule platform, known as TRiM, the enterprise designs synthetic siRNA molecules that silence disease-causing genes in the liver, lungs, and muscle tissue. Through partnerships with global biopharma leaders, Arrowhead Pharmaceuticals is advancing a broad clinical pipeline across cardiovascular and metabolic disorders.